

Evaluation of mammographic surveillance services in women aged 40–49 years with a moderate family history of breast cancer: a single-arm cohort study

SW Duffy,^{1*} J Mackay,² S Thomas,³ E Anderson,⁴
THH Chen,⁵ I Ellis,⁶ G Evans,⁷ H Fielder,³ R Fox,³ G Gui,⁸
D Macmillan,⁹ S Moss,¹ C Rogers,³ M Sibbering,¹⁰
M Wallis,¹¹ R Warren,¹¹ E Watson,¹² D Whyne,⁶
P Allgood¹ and J Caunt¹³

¹Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary, University of London, London, UK

²Department of Biology, University College, London, UK

³Public Health Wales, Cardiff, Wales, UK

⁴Edinburgh Breast Unit, Western General Hospital, Edinburgh, UK

⁵Division of Biostatistics, National Taiwan University, Taipei, China

⁶Department of Histopathology, University of Nottingham, Nottingham, UK

⁷Genetic Medicine, University of Manchester, Manchester, UK

⁸Breast Unit, Royal Marsden Hospital, London, UK

⁹Breast Unit, Nottingham City Hospital, Nottingham, UK

¹⁰General Surgery, Royal Derby Hospital, Derby, UK

¹¹Department of Radiology, Addenbrooke's Hospital, Cambridge, UK

¹²Department of Clinical Health Care, Oxford Brookes University, Oxford, UK

¹³Breast Test Wales, Cardiff, Wales, UK

*Corresponding author



Executive summary

Evaluation of mammographic surveillance services

Health Technology Assessment 2013; Vol. 17: No. 11

DOI: 10.3310/hta17110

NIHR Journals Library

Executive summary

Background

For the last two decades, there has been a perceived need to evaluate the benefit of mammographic surveillance for young women at moderate risk of breast cancer due to family history.

Objectives

We planned to evaluate the policy of annual mammography in women aged 40–49 years with a significant family history of breast or ovarian cancer. The major questions were ‘What is the likely effect of the surveillance on future mortality from breast cancer?’ and ‘At what cost is this effect on mortality achieved?’. The study is referred to as FH01.

Methods

In FH01, we recruited 6710 women between the ages of 40 and 50 years with an estimated personal risk of at least 3%. Women were recruited in 74 surveillance centres from England, Wales, Scotland and Northern Ireland. The women were offered annual mammography for at least 5 years. The age group 40–44 years was targeted so that they would still be aged <50 years after 5 years of surveillance. This was a single-arm cohort study with recruitment taking place between January 2003 and February 2007. The primary study end point was the predicted risk of death from breast cancer as estimated from the size, lymph node status and grade of the tumours diagnosed. The 10-year deaths were estimated using the Nottingham Prognostic Index. The predicted mortality was compared with that of the control group from the UK Breast Screening Age Trial (Age Trial), adjusting for the different underlying incidence in the two populations. In addition, we compared the predicted mortality with a Dutch series of tumours from a similar risk group with ours, and carried out an internal estimation of the predicted mortality over 20 years using Markov process models.

Results

As of December 2010, there were 165 breast cancers diagnosed in 37,025 person-years of observation and 30,556 mammographic screening episodes. Recall rates for assessment were 8% at prevalence screens and 6% at incidence screens. Cancer detection rates were 5 per 1000 at prevalence screens and 4 per 1000 at incidence screens. Of these, 122 (74%) were diagnosed at screening, 39 (24%) were interval cancers and 4 (2%) were diagnosed in non-attenders (symptomatic diagnosis after failure to attend for the most recent screen offered). The cancers included 44 (26%) cases of ductal carcinoma in situ. Cancers in FH01 were significantly smaller ($p = 0.004$), less likely to be node positive ($p = 0.003$) and of a more favourable histological grade ($p = 0.002$) than the Age Trial control patients. There were 24 predicted deaths in 37,025 person-years in FH01, with an estimated incidence of 6.3 per 1000 per year. The corresponding figures for the Age Trial control group were 204 predicted deaths in 622,127 person-years and an incidence of 2.4 per 1000 per year. This gave an estimated 40% reduction in breast cancer mortality [relative risk = 0.60; 95% confidence interval (CI) 0.37 to 0.98; $p = 0.04$]. This was achieved with recall rates, preoperative diagnosis rates and radiation doses, which would be acceptable in the National Health Service Breast Screening Programme. The Markov model results indicated a 31–34% reduction in

future breast cancer mortality over 20 years, and 320–357 life-years saved (256–286 years after quality adjustment). Depending on assumptions, estimated costs ranged from £4435 (95% CI £3426 to £6234) to £5450 (95% CI £4154 to £7878) per quality-adjusted life-year saved.

Conclusions

Annual mammographic surveillance in women aged 40–49 years with an increased familial risk of breast cancer is likely to bring about a substantial reduction in mortality from breast cancer and to be cost-effective. There is a need to further standardise familial risk assessment, to research the impact of digital mammography and to clarify the role of breast density in this population.

Trial registration

This study is registered as National Research Register N0484114809.

Funding

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.

Publication

Duffy SW, Mackay J, Thomas S, Anderson E, Chen THH, Ellis I, *et al.* Evaluation of mammographic surveillance services in women aged 40–49 years with a moderate family history of breast cancer: a single-arm cohort study. *Health Technol Assess* 2013;**17**(11).

Health Technology Assessment

ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

Five-year impact factor: 5.596

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the ISI Science Citation Index and is assessed for inclusion in the Database of Abstracts of Reviews of Effects.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (<http://www.publicationethics.org/>).

Editorial contact: nihredit@southampton.ac.uk

The full HTA archive is freely available to view online at <http://www.hta.ac.uk/project/htapubs.asp>. Print copies can be purchased from the individual report pages.

Criteria for inclusion in the *Health Technology Assessment* journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA programme findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'.

For more information about the HTA programme please visit the website: <http://www.hta.ac.uk/>

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 01/18/01. The contractual start date was in September 2002. The draft report began editorial review in February 2011 and was accepted for publication in August 2012. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen's Printer and Controller of HMSO 2013. This work was produced by Duffy *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library, produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).

Editor-in-Chief of *Health Technology Assessment* and NIHR Journals Library

Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

NIHR Journals Library Editors

Dr Andree Le May Chair of NIHR Journals Library Editorial Group

Professor Ken Stein Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Dr Martin Ashton-Key Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

Professor Aileen Clarke Professor of Health Sciences, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK

Dr Peter Davidson Director of NETSCC, HTA, UK

Ms Tara Lamont Scientific Advisor, NETSCC, UK

Dr Tom Marshall Reader in Primary Care, School of Health and Population Sciences, University of Birmingham, UK

Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads Honorary Professor, Business School, Winchester University and Medical School, University of Warwick, UK

Professor Jane Norman Professor of Maternal and Fetal Health, University of Edinburgh, UK

Professor John Powell Senior Clinical Researcher, Department of Primary Care, University of Oxford, UK

Professor James Raftery Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts Professorial Research Associate, University College London, UK

Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Editorial contact: nihredit@southampton.ac.uk